comparemela.com

Latest Breaking News On - Asco annual meeting - Page 4 : comparemela.com

Advent of PARP Inhibitors in Metastatic CRPC

Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting.

Treatment approachesProstate cancerMetastatic prostate cancerCastration resistant prostate cancerParp inhibitorsParp inhibitionTissue biopsyLiquid biopsySomatic testingGermline testingCirculating tumor dnaCell free dnaAdverse eventsDrug adverse eventTalapro 2Arsi therapy

Bispecifics in Multiple Myeloma: Adverse Event Management

Expert perspectives on adverse event management in patients on bispecific therapy for multiply relapsed multiple myeloma.

Evolving treatment paradigmMultiple myelomaRecent updatesAdverse event managementMyeloma cancerRelapsed refractory multiple myelomaMultiply relapsedLater line treatmentLater line therapyAdverse eventsDrug adverse eventCytokine release syndromeImmune effector cell associated neurotoxicity syndromeProphylactic treatmentAsco 2023Asco annual meeting

Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting

Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.

Translating recent evidenceReal world managementRefractory diffuse largeb cell lymphomaLargeb cell lymphomaMoving novel therapyDiffuse largeb cell lymphomaRelapsed refractory dlbclRr dlbclL mind studyL mind trialTl mindR chopFront mindFront mind studyFront mind trialZuma 7

Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy

A panel of expert oncologists present the case of a 78-year-old woman who is treated with lurbinectedin following disease progress on first-line carboplatin, etoposide, and atezolizumab.

Evolving treatment strategiesSmall cell lung cancerLurbinectedin followingEs sclcExtensive stage small cell lung cancerSecond lineDisease progressionAsco 2023Asco annual meeting

Bispecifics in Multiple Myeloma: Dosing and Transition of Care

A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.

Evolving treatment paradigmMultiple myelomaRecent updatesMyeloma cancerRelapsed refractory multiple myelomaMultiply relapsedLater line treatmentLater line therapyFixed duration therapyDuration of therapyDuration of treatmentStep up dosingPriming dosesDose scheduleDosing scheduleAccess to care

vimarsana © 2020. All Rights Reserved.